CD274 and non-small cell lung carcinoma: PD-L1 is a common and effective clinical predictor that can guide the use of immune checkpoint inhibitors (ICIs) for the treatment of non-small cell lung cancer (NSCLC) due to its robust performance as an immunotherapy biomarker (Hurkmans et al. 2020).